Behcet's disease uveitis

被引:1
|
作者
Joubert, M. [1 ]
Desbois, A. -C. [1 ]
Domont, F. [1 ]
Ghembaza, A. [1 ]
Lejoncour, A. [1 ]
Mirouse, A. [1 ]
Maalouf, G. [1 ]
Leclercq, M. [3 ]
Touhami, S. [2 ]
Cacoub, P. [1 ]
Bodaghi, B. [2 ]
Saadoun, D. [1 ]
机构
[1] Sorbonne Univ, Pitie Salpetriere Univ Hosp, AP HP, UMRS 959 83,Inserm,Ctr reference Malad Autoinflamm, Blvd Hop, F-75013 Paris, France
[2] Sorbonne Univ, Pitie Salpetriere Univ Hosp, Dept Ophtalmol, Paris, France
[3] CHU Rouen, Internal Med Dept, F-76000 Rouen, France
来源
REVUE DE MEDECINE INTERNE | 2023年 / 44卷 / 10期
关键词
Uveitis; Vasculitis; Biotherapies; Anti-TNFa agents; LONG-TERM EFFICACY; NECROSIS FACTOR-ALPHA; INTRAVITREAL INFLIXIMAB; OCULAR MANIFESTATIONS; NONINFECTIOUS UVEITIS; INTERFERON ALPHA-2A; CYCLOSPORINE-A; REMISSION INDUCTION; REFRACTORY UVEITIS; TNF-ALPHA;
D O I
10.1016/j.revmed.2023.06.004
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Uveitis in Behc, et's disease (BD) is frequent (40% of cases) and is a major cause of morbidity. The age of onset of uveitis is between 20 and 30 years. Ocular involvement includes anterior, posterior or panuveitis. It is non-granulomatous. Uveitis may be the first sign of the disease in 20% of cases or it may appear 2 or 3 years after the first symptoms. Panuveitis is the most common presentation and is more commonly found in men. Bilateralisation usually occurs on average 2 years after the first symptoms. The estimated risk of blindness at 5 years is 10-15%. BD uveitis has several ophthalmological features that distinguish it from other uveitis. The main goals in the management of patients are the rapid resolution of intraocular inflammation, prevention of recurrent attacks, achievement of complete remission, and preservation of vision. Biologic therapies have changed the management of intraocular inflammation. The aim of this review is to provide an update previous article by our team on pathogenesis, diagnostic approaches, identification of factors associated with relapse and the therapeutic strategy of BD uveitis.(c) 2023 Societe Nationale Franc, aise de Medecine Interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:546 / 554
页数:9
相关论文
共 50 条
  • [31] Hyperhomocysteinaemia is associated with uveitis but not with deep venous thrombosis in Behcet's disease
    Feki, M
    Houman, H
    Ghannouchi, M
    Smiti-Khanfir, M
    Hamzaoui, K
    El Matri, L
    Mebazaa, A
    Kaabachi, N
    [J]. CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2004, 42 (12) : 1417 - 1423
  • [32] Short-term chlorambucil for refractory uveitis in Behcet's disease
    Mudun, AB
    Ergen, A
    Ipcioglu, SU
    Burumcek, EY
    Durlu, Y
    Arslan, MO
    [J]. OCULAR IMMUNOLOGY AND INFLAMMATION, 2001, 9 (04) : 219 - 229
  • [33] Risk factors, clinical features and treatment of Behcet's disease uveitis
    Zhong, Zhenyu
    Su, Guannan
    Yang, Peizeng
    [J]. PROGRESS IN RETINAL AND EYE RESEARCH, 2023, 97
  • [34] ETANERCEPT THERAPY IN PATIENTS WITH REFRACTORY BEHCET'S DISEASE: UVEITIS AND BEYOND
    Mohammed, R. H. A.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 486 - 487
  • [35] Infliximab therapy in Behcet?s uveitis
    Alizadegan, F.
    Yalcinbayir, O.
    Gunduz, G. Ucan
    Pehlivan, Y.
    [J]. JOURNAL FRANCAIS D OPHTALMOLOGIE, 2022, 45 (09): : 1036 - 1041
  • [36] Comparison of pediatric patients with idiopathic uveitis, and uveitis due to juvenile idiopathic arthritis and Behcet's disease
    Yildirim, Deniz Gezgin
    Hasanreisoglu, Murat
    Bakkaloglu, Sevcan A.
    [J]. POSTGRADUATE MEDICINE, 2023, 135 (01) : 79 - 85
  • [37] Comment on "Classification Criteria for Behcet Disease Uveitis"
    Tugal-Tutkun, Ilknur
    Onal, Sumru
    Gul, Ahmet
    [J]. AMERICAN JOURNAL OF OPHTHALMOLOGY, 2022, 235 : 336 - 338
  • [38] Infliximab treatment of resistant uveitis in Behcet disease
    Becvar, R.
    Landova, A.
    Rihova, E.
    [J]. PRESSE MEDICALE, 2013, 42 (04): : 690 - 690
  • [39] An Algorithm for the Diagnosis of Behcet Disease Uveitis in Adults
    Tugal-Tutkun, Ilknur
    Onal, Sumru
    Stanford, Miles
    Akman, Mehmet
    Twisk, Jos W. R.
    Boers, Maarten
    Oray, Merih
    Ozdal, Pinar Cakar
    Kadayifcilar, Sibel
    Amer, Radgonde
    Rathinam, Sivakumar R.
    Vedhanayaki, Rajesh
    Khairallah, Moncef
    Akova, Yonca
    Yalcindag, Fatime Nilufer
    Kardes, Esra
    Basarir, Berna
    Altan, Cigdem
    Ozyazgan, Yilmaz
    Gul, Ahmet
    [J]. OCULAR IMMUNOLOGY AND INFLAMMATION, 2021, 29 (06) : 1154 - 1163
  • [40] INCIDENCE OF UVEITIS DUE TO BEHCET DISEASE AND COMPLICATIONS
    Kabasele, Paul Muambi Buana
    Taylor, Simon Richard
    Lightman, Susan Louise
    [J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2010, 28 (04) : S146 - S146